Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Ryan Fukushima sold 10,000 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the completion of the transaction, the chief executive officer owned 201,047 shares of the company's stock, valued at $12,062,820. This represents a 4.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Fukushima also recently made the following trade(s):
- On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The stock was sold at an average price of $44.07, for a total value of $597,148.50.
Tempus AI Stock Down 4.7%
TEM opened at $57.27 on Thursday. The stock's fifty day moving average is $50.92 and its 200-day moving average is $54.35. The company has a market capitalization of $10.28 billion, a PE ratio of -33.30 and a beta of 3.46. Tempus AI, Inc. has a one year low of $41.73 and a one year high of $104.32. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31.
Tempus AI (NASDAQ:TEM - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The business had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business's quarterly revenue was up 36.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.24) earnings per share. On average, equities analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of Tempus AI in a research note on Wednesday, June 17th. Needham & Company LLC restated a "buy" rating and set a $75.00 price target on shares of Tempus AI in a research note on Monday, June 1st. Jefferies Financial Group initiated coverage on Tempus AI in a report on Monday, April 13th. They set an "underperform" rating and a $35.00 price objective on the stock. Guggenheim decreased their target price on Tempus AI from $95.00 to $60.00 and set a "buy" rating for the company in a research report on Monday, March 30th. Finally, HC Wainwright lowered their target price on shares of Tempus AI from $95.00 to $64.00 and set a "buy" rating on the stock in a research note on Monday, May 11th. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $68.54.
Check Out Our Latest Stock Analysis on TEM
Hedge Funds Weigh In On Tempus AI
Several hedge funds and other institutional investors have recently modified their holdings of the stock. CoreCap Advisors LLC boosted its position in Tempus AI by 293.4% in the second quarter. CoreCap Advisors LLC now owns 1,019 shares of the company's stock valued at $59,000 after buying an additional 760 shares in the last quarter. NewEdge Advisors LLC increased its stake in shares of Tempus AI by 1.3% in the first quarter. NewEdge Advisors LLC now owns 42,996 shares of the company's stock valued at $1,944,000 after buying an additional 536 shares in the last quarter. Avidity Partners Management LP acquired a new position in Tempus AI during the 1st quarter worth about $1,130,000. Silverback Asset Management LLC increased its position in Tempus AI by 44.5% in the 1st quarter. Silverback Asset Management LLC now owns 35,700 shares of the company's stock valued at $1,614,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Vestor Capital LLC lifted its position in shares of Tempus AI by 338.2% during the first quarter. Vestor Capital LLC now owns 1,538 shares of the company's stock worth $70,000 after purchasing an additional 1,187 shares in the last quarter. Institutional investors own 24.22% of the company's stock.
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
